SCHEMBL3450314

SCHEMBL3450314

COc1ncc(-c2cnc(Nc3cccc(Cl)c3)nc2-n2nc(C(F)(F)F)cc2C)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 11/20 0.43
SYK P43405 6/20 0.42
TYRO3 Q06418 1/20 0.41
MERTK Q12866 1/20 0.41
EGFR P00533 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
ABL1 P00519 1/20 0.39
ERBB2 P04626 1/20 0.39
NTRK1 P04629 1/20 0.39
GNAI2 P04899 1/20 0.39
LCK P06239 1/20 0.39
RET P07949 1/20 0.39
HCK P08631 1/20 0.39
ROS1 P08922 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39
GABRA1 P14867 1/20 0.39
FER P16591 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447752 0.94 CNR2 (0.43) CNR2SYKTYRO3MERTKCYP1A2
SCHEMBL3450670 0.92 SYK (0.43) SYK
SCHEMBL3449007 0.91 EGFR (0.41) SYKTYRO3MERTKEGFRPLK4
SCHEMBL3450452 0.91 SYK (0.45) SYKEGFRLCKBTK
SCHEMBL3374715 0.90 SYK (0.44) SYK
SCHEMBL3449516 0.90 SYK (0.44) SYKEGFRAURKALCKPTK2
SCHEMBL3448623 0.89 SYK (0.39) CNR2SYKEGFRPLK4AURKA
SCHEMBL13311977 0.89 SYK (0.41) CNR2SYKABL1LCKBTK
SCHEMBL3451676 0.89 CNR2 (0.43) CNR2SYKEGFRBTK
SCHEMBL3374247 0.87 SYK (0.47) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CNR2 517/4885SYK 804/4885TYRO3 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.